Garcinia cambogia for Health & Longevity - Quick Reference Sheet
evipedia.ai
← Back

Garcinia cambogia for Health & Longevity

Created on 08/25/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5 – Audit

A tropical fruit rind extract that blocks one step in building fat from surplus sugar. Pooled trial evidence supports a small short-term drop in body weight and a favourable shift in blood fats alongside a reduced-calorie diet. Against that sits documented liver damage severe enough to require hospitalisation. For someone already optimising metabolic health, the demonstrated gain is small. (Full Review)

Protocol

Standard practitioner protocol
500 mg × 3 daily
1,500 mg hydroxycitric acid total, alongside a defined calorie deficit rather than as a standalone measure
Best time of day
30–60 min before meals
Meal-anchored rather than clock-anchored; a meal cuts exposure two- to threefold
Baseline biomarkers guiding use
Normal liver enzymes
A precondition; elevated triglycerides and elevated leptin identify the profile in which measurable benefit was observed
Time to effect
Body weight and body-mass index
8–12 weeks
Nothing meaningful should be expected in the first month
Blood lipid profile
Beyond 8 weeks
Effects were larger in interventions running beyond eight weeks
Visceral fat area
8–16 weeks
Reductions were measured at eight weeks and at sixteen weeks; no rebound followed withdrawal

Benefits

Contraindications
  • Active or chronic liver disease (steatohepatitis, cirrhosis Child-Pugh class A–C, hepatitis B or C)
  • Prior drug-induced or herb-induced liver injury from any agent
  • Baseline ALT or AST above twice the upper limit of normal
  • Known HLA-B*35:01 carriers
  • Any monoamine oxidase inhibitor, or within 14 days of stopping one
  • Bipolar disorder or any psychotic-spectrum diagnosis
  • History of acute pancreatitis
  • Pregnancy, breastfeeding, or trying to conceive
  • Children and adolescents under 18
    •
Key Interactions
  • Selective serotonin and serotonin-noradrenaline reuptake inhibitors (fluoxetine, sertraline, escitalopram, venlafaxine, duloxetine)
  • Other serotonergic agents (triptans such as sumatriptan, tramadol, dextromethorphan, St John's wort)
  • Known liver-damaging drugs (acetaminophen, methotrexate, isoniazid, amiodarone, high-dose statins)
  • Montelukast
  • Drugs cleared by CYP2B6 (bupropion, efavirenz, ketamine, methadone)
  • Warfarin and direct oral anticoagulants (apixaban, rivaroxaban, edoxaban, dabigatran)
  • Diabetes medications (insulin, sulfonylureas, metformin)
  • Over-the-counter agents (acetaminophen, dextromethorphan-containing cough remedies, stimulant weight-loss aids)
  • Supplement interactions - additive fat-loss and lipid agents (green tea extract, synephrine, chromium)
  • Supplement interactions - additive serotonergic agents (5-hydroxytryptophan, tryptophan, S-adenosylmethionine, St John's wort)
  • Supplement interactions - additive liver load (ashwagandha, red yeast rice, turmeric extracts, black cohosh)
  • Other interventions (aggressive caloric restriction, ketogenic protocols, prolonged fasting)

Risk & Side Effects

  • High: Drug-induced liver injury
    •
  • Medium: Gastrointestinal adverse effects; product adulteration and label inaccuracy
  • Low: Serotonin toxicity with serotonin-raising medicines; mania and hypomania
  • Speculative: Acute pancreatitis; testicular toxicity at high doses

Monitoring

Marker Target Why
ALT (alanine aminotransferase) Men <25 U/L; women <20 U/L Most specific marker of liver-cell injury
AST (aspartate aminotransferase) <25 U/L Confirms the liver-cell injury pattern alongside ALT
ALP 45–90 U/L Distinguishes bile-flow from liver-cell injury
Total bilirubin <1.0 mg/dL Marks functional liver failure rather than enzyme leak
GGT <25 U/L Sensitive early marker of liver stress and oxidative load
INR 0.9–1.1 Detects loss of liver synthetic capacity
Fasting triglycerides <80 mg/dL Primary lipid endpoint this intervention moves
HDL-C Men >50 mg/dL; women >60 mg/dL Secondary lipid endpoint with a demonstrated small rise
Apolipoprotein B <80 mg/dL Counts artery-clogging particles directly
Fasting insulin 2–5 µIU/mL Detects the adverse blood-sugar shift seen in women and in obesity
HbA1c <5.4% Confirms no drift in glucose control over a full course
Waist circumference Men <94 cm; women <80 cm Tracks the visceral fat depot the imaging trials moved
Body weight Change from own baseline; no fixed target Primary efficacy endpoint in every trial

Cadence: Baseline within four weeks of starting; liver panel repeated at four to six weeks and again at the end of a 12-week course; metabolic markers repeated at 12 weeks; weight and waist circumference weekly at home; any unscheduled liver panel within 48 hours of symptom onset

Qualitative Assessment

  • Energy levels and unexplained fatigue, which is often the first non-specific symptom of liver injury
  • Appetite and between-meal hunger, the mechanism most often claimed and least often confirmed
  • Sleep quality and onset latency, given the serotonergic mechanism
  • Mood stability, elevation, irritability or racing thoughts, which preceded the reported mania cases
  • Skin and eye colour, urine darkness and stool pallor, checked weekly in daylight
  • Right-upper-abdominal discomfort or new itching
  • Gastrointestinal tolerance: nausea, cramping and stool consistency
  • Tremor, sweating or agitation, the early triad of serotonin excess
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.